The upsized offering has put Beta Bionics at the higher end of healthcare IPOs in the past year, the sharp end especially for ...

GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering.

The GSV Ventures- and Westbridge Capital-backed firm became a unicorn in 2022 and is now valued at $1.14 billion. The company ...

Companies are pushing ahead with their initial public offerings (IPOs) by compromising on valuations and reducing their issue ...

Beta Bionics announced today that it went public after pricing a significantly upsized initial public offering (IPO).

At the closing bell, Metsera’s stock MTSR stood at $26.50, well above its IPO pricing level of $18. It opened on the Nasdaq ...

Median returns three months post IPO 2024 performance (the green line in Chart 5) were much better than the last two years (purple and pink lines). Importantly, 2024 IPOs as a group have so far held ...

HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...

Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO).

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...